Lupin Limited · NSE:LUPIN
Lupin — Q3 FY2021 Earnings Presentation
14 slides from Lupin's earnings presentation, Jan 28, 2021
Slide 1: Exchange filing cover letter for Q3 FY2021 Investor Presentation
January 28, 2021 BSE Limited Department of Corporate Services, P. J. Towers, Dalal Street, MU BAI- 400 001. ational Stock Exchange of India Limited Exchange Plaza, Bandra Kurio Complex, Bandra (East), Mumbai - 400 051 . Dear Sir/Madam, Sub: Q3 FY2021 Investor Presentation. Pursuant to Regulation 30(
Slide 2: Investor Presentation Q3 FY2021
Investor Presentation Q3 FY2021 January 28, 2021
Slide 3: Safe Harbor Statement
Safe Harbor Statement Materials and information provided during this presentation may contain ‘forward-looking statements’. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to diffe
Slide 4: Lupin – Awards and Accolades
Lupin – Awards and Accolades • Vinita Gupta named among Most Powerful Women in Business in India – #7 by Fortune India • India Pharma Leader Award - India Pharma 2020 and India Medical Device 2020 conference organized by FICCI and the Ministry of Chemicals and Fertilizers, GOI • Lupin ranked No.1 in
Slide 5: Q3 FY2021 Snapshot
Q3 FY2021 Snapshot Important developments Sales (INR mn, YoY Growth) Commercial Mr. Nilesh.D.Gupta • Resilient US generics business registered growth despite Managing Director India, North America, limited seasonal products uptake Lupin Limited 13,669, 5% 14,424, 5% • Albuterol ramped up to 8%+ gene
Slide 6: Strategic Vision
Strategic Vision Well Diversified Pharma Company Integrated Global Quality Culture Novel products North America NaMuscla Novel Oncology Women’s Health Franchise Research Platform Committed to building Capability building and Geographic expansion Pipeline acceleration robust specialty portfolio expan
Slide 7: Q3 FY2021 Financial Results Review
Q3 FY2021 Financial Results Review
Slide 8: P&L Highlights – Q3 FY2021
P&L Highlights – Q3 FY2021 % of QoQ % of % of YoY Amount in INR mn Q3 FY21 Q2 FY21 Q3 FY20 sales growth sales sales growth Net sales 39,173 100.0% 37,818 100.0% 3.6% 37,161 100.0% 5.4% Other operating income 1,001 532 532 Total revenue 40,174 38,350 4.8% 37,693 6.6% Gross profit 25,423 64.9% 24,001
Slide 9: North America
Q3FY21 North America 37% YoY 4.8% QoQ 3.1% Resilient generics business Consolidating our position in the US2 US quarterly sales (US$ mn) #4 #3 #3 #3 212 140 6 186 180 188 120 #4 5 157 28.8% average #5 129 123 121 100 4 109 market share2 80 3 60 79 83 40 65 63 62 2 44 45 51 20 1 0 0 2015-16 2016-17 2
Slide 10: India
Q3FY21 India 35% YoY 5.4% QoQ 2.6% Consistent Outperformer Leadership across cardiac, diabetes, and respiratory India quarterly Sales (INR bn) Q3 FY21 5 Year CAGR % Lupin Rank1 (YoY% growth) MAT MAT 13.7 Therapy Market Lupin 13.0 12.9 13.3 8.8 Dec-15 Dec-20 11.9 Acute 7% 4% 13 15 8.2 Chronic 11% 14%
Slide 11: Developed and Emerging Markets, API and Global Institutional
Other Markets • Germany: EUR 8.1 mn sales in Q3 FY21 EU5 • Developed Our 1st biosimilar Nepexto® (bEtanercept) launched in Germany through commercial partner • ARVs, Inhalation and CNS are the key focus therapeutic segments • 4th largest generics player3 Australia • Q3 FY21 revenues of AU$ 15.7 mn (
Slide 12: R&D – Higher focus on complex products and FTFs
R&D – Higher focus on complex products and FTFs Invested INR 3.5 bn or 8.9% of sales on R&D in Q3 FY21 at 7 R&D sites globally Optimizing R&D spend US Pipeline 11.5% 4.5 10.3% 12.0% 4.0 10.2% 437 cumulative filings 9.1% 8.9% 10.0% 3.5 3.0 8.0% 2.5 4.3 6.0% 2.0 3.8 3.4 3.6 3.5 152 pending approval 1.
Slide 13: Manufacturing and R&D – Diverse Global Network
Manufacturing and R&D – Diverse Global Network Global Commercial Presence 100 23 7 Countries where Countries with Countries with OPERATIONS products are sold marketing offices subsidiaries RESEARCH 15 7 Manufacturing Sites R&D Sites ◼ 12 USFDA inspected sites ◼ 437 US ANDAs; 285 approved ◼ 30 bn+ ex
Slide 14: Thank you
Thank you Registered Office Lupin Limited, 3rd Floor, Kalpataru Inspire, Off. Western Expressway Highway Santacruz (East), Mumbai 400 055, India. www.lupin.com www.twitter.com/LupinGlobal www.linkedin.com/company/lupin/ www.facebook.com/LupinWorld/ Phone: +91 22 6640 2323 | Fax: +91 22 6640 2051